The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ ...

Moderna (MRNA) Outperforms Broader Market: What You Need to Know. In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple surveillance systems.

“After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,” HHS Communications Director Andrew Nixon ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40% share price gain in 2025.